Investment archive

Investment feed — page 33

Back to latest investments

Opsin Announces $21M to Govern Enterprise AI Agents

Opsin Announces $21M to Govern Enterprise AI Agents

SYN Ventures and Race Capital lead Opsin's $21M funding announcement. The security startup connects agent permissions and behavior; stage and valuation remain undisclosed.

Abby Care Closes $82M Series C for Family-Led Care at Home

Abby Care Closes $82M Series C for Family-Led Care at Home

Transformation Capital leads Abby Care's reported $82M Series C. The company confirms the close as it expands clinically supported, paid family caregiving.

Mueon Raises $65M Series A to Take Cubelets Toward Production

Mueon Raises $65M Series A to Take Cubelets Toward Production

Maverick Silicon leads Mueon's $65M Series A. The capital funds validation and production readiness—not proof that its 10x efficiency target is achieved.

OrbiMed Asia Partners VI raises over $1B

OrbiMed Asia Partners VI raises over $1B

Separate Asian vehicle within the announced two-fund fundraising; not a credit facility or a company financing.

Aldaron Fund I confirmed $884M final close; $67M separate co-investments

Aldaron Fund I confirmed $884M final close; $67M separate co-investments

Aldaron first disclosed its debut private-equity fund in October 2026. Its manager-issued November 9 FINAL-close announcement confirms $884M of Fund I commitments, including $850M from LPs, plus a SEPARATE $67M co-investment commitment for its earlier Oak Point deal. $951M is the combined manager-wide total, not the vehicle's size or new startup funding. Exact legal closing day remains unverified.

OrbiMed Private Investments X raises over $1.9B

OrbiMed Private Investments X raises over $1.9B

One of two distinct vehicles in OrbiMed’s approximately $3B announced commitments. LP names reported for the combined fundraising are not attributed to either individual vehicle.

OMass Therapeutics announces $310M Series C

OMass Therapeutics announces $310M Series C

Confirmed company-announced Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings. Financing supports investigational clinical development, not approved therapies.

Ramp confirms $1.85B primary financing at $60B valuation

Ramp confirms $1.85B primary financing at $60B valuation

Ramp confirmed the $1.85B primary financing on October 15, following initial reporting on October 9. Dragoneer led, Thrive and other named firms co-led, and Lightspeed and Stripes participated. This is one financing, not two rounds.

Qilimanjaro Quantum Tech completes €19.6M Series A first close

Qilimanjaro Quantum Tech completes €19.6M Series A first close

Qilimanjaro Quantum Tech completes €19.6M Series A first close

Zenzap announces $44M Series A led by Lightspeed

Zenzap announces $44M Series A led by Lightspeed

Lightspeed led Zenzap's $44M Series A. Bessemer, which backed the company from inception, continued participating. The amount is the entire round.

Evos announces $9M pre-seed

Evos announces $9M pre-seed

Evos announced a $9M pre-seed on October 14, 2026, co-led by Uncork Capital and Field Ventures. Crosslink participated alongside Utopia Capital Management and Sandwith Ventures.

Probably Genetic Raises $12M Series A for Rare-Disease Data

Probably Genetic Raises $12M Series A for Rare-Disease Data

Fierce Healthcare reported Probably Genetic's $12M Series A led by Threshold Ventures, with Y Combinator and other existing investors. The separate earlier ARPA-H research award is not included.